Literature DB >> 11953616

Giant cell tumor of long bone: a Canadian Sarcoma Group study.

Robert E Turcotte1, Jay S Wunder, Marc H Isler, Robert S Bell, Norman Schachar, Bassam A Masri, Guy Moreau, Aileen M Davis.   

Abstract

A multicentric retrospective study of giant cell tumor of bone was conducted among Canadian surgeons. The hypothesis was that no differences would be found in health status, function, or recurrence rate irrespective to the nature of filling material or adjuvant used in patients treated with curettage. One hundred eighty-six cases were collected. There were 96 females and 90 males. The mean age of the patients was 36 years (range, 14-72 years), the minimum followup was 24 months, and the median followup was 60 months. Sixty-two percent of the tumors involved the knee region. One hundred fifty-eight were primary tumors and 28 were recurrences. Campanacci grading was as follows: Grade 1, seven patients; Grade 2, 100 patients; Grade 3, 76 patients; and unknown in three patients. Fifty-six patients had a pathologic fracture. Resection was done in 38 patients and 148 patients had curettage. The latter was supplemented with high speed burring in 135 patients, cement in 64 patients, various combinations of autograft or allograft bone in 61 patients, phenol in 37 patients, and liquid nitrogen in 10 patients. Structural allografts were used in 25 patients. The overall recurrence rate was 17%, 18% after curettage, and 16% after resection. Patients with primary tumors treated with curettage had a 10% recurrence rate. For recurrent lesions treated by curettage, the recurrence rate was 35%. The nature of the filling material used or the type of adjuvant method used or any combination of both failed to show any statistical impact on the recurrence risk. The results from the Musculoskeletal Tumor Society rating from 1987 were significantly lower in patients who sustained a displaced fracture. Results from the bodily pain section of the Short Form-36 also were found to be lower when a pathologic fracture was present. Results from the Musculoskeletal Tumor Society Rating 1987, the Short Form-36, and the Toronto Extremity Salvage Score did not show differences when either cement or bone graft were used after curettage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953616     DOI: 10.1097/00003086-200204000-00029

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  106 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

2.  Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.

Authors:  Yu-Peng Liu; Kang-Hua Li; Bu-Hua Sun
Journal:  Clin Orthop Relat Res       Date:  2012-07-07       Impact factor: 4.176

3.  Comparison of the degenerative changes in weight-bearing joints following cementing or grafting techniques in giant cell tumour patients: medium-term results.

Authors:  K Szalay; I Antal; J Kiss; M Szendroi
Journal:  Int Orthop       Date:  2006-09-13       Impact factor: 3.075

Review 4.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

5.  Management of giant cell tumor of bone: computerized tomography based selection strategy and approaching the lesion through the site of cortical break.

Authors:  Dominic K Puthoor; Kishore Puthezhath
Journal:  Orthop Surg       Date:  2012-05       Impact factor: 2.071

6.  Ossified soft tissue recurrence of giant cell tumor of the bone: four case reports with follow-up radiographs, CT, ultrasound, and MR images.

Authors:  Sun-Young Park; Min Hee Lee; Jong Suk Lee; Joon Seon Song; Hye Won Chung
Journal:  Skeletal Radiol       Date:  2014-05-11       Impact factor: 2.199

7.  Joint preservation after extensive curettage of knee giant cell tumors.

Authors:  Miguel A Ayerza; Luis A Aponte-Tinao; German L Farfalli; Carlos A Lores Restrepo; D Luis Muscolo
Journal:  Clin Orthop Relat Res       Date:  2009-06-10       Impact factor: 4.176

8.  Conservative treatment of Campanacci grade III proximal humerus giant cell tumors.

Authors:  Richard D Lackman; Eileen A Crawford; Joseph J King; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2008-11-06       Impact factor: 4.176

9.  Curettage of benign bone tumors without grafts gives sufficient bone strength.

Authors:  Takashi Yanagawa; Hideomi Watanabe; Tetsuya Shinozaki; Kenji Takagishi
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

10.  Treatment and outcome of giant cell tumors of the pelvis.

Authors:  Maurice Balke; Arne Streitbuerger; Tymoteusz Budny; Marcel Henrichs; Georg Gosheger; Jendrik Hardes
Journal:  Acta Orthop       Date:  2009-10       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.